Moderna, Inc.(MRNA) - Stock detail

Moderna, Inc.

US
MRNA
Moderna, Inc.(Listing date: 12/07/2018)

Moderna, Inc. was incorporated under Delaware law on July 22, 2016. The company is a leader in the field of messenger ribonucleic acid (mRNA) medicine. Through more than a decade of work at the intersection of science, technology, and health, the company has developed drugs with unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. The company's mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a unique culture and a global team driven by Moderna's values and mindset, the company strives to transform the future of human health in a responsible manner and to deliver the greatest possible impact to people through mRNA medicines.

AI Technical AnalystHold
Rating4/10
Generated at:2026-06-03 17:40:48
Analysis based on real-time data for Moderna, Inc. (MRNA) on the US Stock Market (NASDAQ). Data analysis period from 2026-03-10 to 2026-06-03, covering 86 calendar days and 60 trading days. Chip distribution data is an estimate based on historical OHLC price and turnover behavior, using a volume-based proxy model, and should be interpreted with caution as it is not official shareholder registry data.
Insight

Technical indicators show a mixed but cautiously improving picture following a significant recent price surge, with short-term momentum turning bullish but requiring further confirmation.

Resistance
59.48
Support
43.68
Support and resistance are estimated from the latest 60 sessions.
Strategy
  • Short-term:For existing holders, maintain positions as further upside toward the $53-$55 resistance zone is plausible. For new investors, wait for a potential pullback to support levels (e.g., $47.00 - $47.50, near the EMA cluster) for a better risk-reward entry point, or for a confirmed breakout above the $50.00-$50.50 level with strong volume, due to elevated short-term overbought conditions.
  • Mid-term:Monitor the stock's ability to consolidate above the $48 level and challenge higher resistance. A confirmed breakout above key resistance levels with strong volume and a shift in the long-term moving average alignment would be needed for a more bullish medium-term outlook.
  • Long-term:The long-term technical structure remains bearish with a death cross formation in moving averages. Long-term investment decisions should be heavily weighted by fundamental factors, clinical trial news, regulatory updates, and product sales data, given the stock's event-driven nature and high volatility.

Moving averages

MA 5
47.10
MA 20
48.68
MA 60
50.43
Price
49.06
AI Analysis
  • Simple moving averages show a bearish alignment (death cross formation) with longer-term averages above shorter-term ones: MA_60 (50.43) > MA_20 (48.68) > MA_10 (47.24) > MA_5 (47.10), indicating a prevailing intermediate-term downtrend.
  • The closing price on 2026-06-03 ($49.06) has broken above the 5-day, 10-day, and 20-day MAs, which is a short-term bullish signal.
  • Exponential Moving Averages (EMA_5: 47.36, EMA_10: 47.48, EMA_20: 48.12) tell a similar story, with the price now trading above all three, suggesting recent momentum is positive.

Volume

Volume
6.91M
20D Avg
7.64M
Institution
-
Participation
-
AI Analysis
  • The dramatic price moves in early May (2026-05-08 and 2026-05-11) were accompanied by massive volume spikes (20.78M and 24.05M shares respectively), indicating high institutional interest or news-driven trading.
  • The volume on the recent rebound day (2026-06-03) was a solid 6.9M shares, above the recent average but not at climactic levels.
  • This suggests the buying was strong but not exhaustive, potentially leaving room for further upside if volume expands.
  • The decline to the $45.64 low occurred on relatively lower volume (5.68M), a positive sign that selling pressure was waning.

MACD

MACD
-0.83
Signal
-0.84
Hist
0.01
Trend
-
AI Analysis
  • The MACD line is at -0.8334, with the signal line at -0.8398, resulting in a very small positive histogram (MACDH) of 0.0065.
  • This indicates that the bearish momentum is decelerating and a potential bullish crossover is imminent.
  • While the MACD remains in negative territory, this convergence is a classic early sign of a possible trend reversal from down to up.

Bollinger bands

Upper
53.58
Middle
48.68
Lower
43.78
Width
20.14%
AI Analysis
  • The closing price of $49.06 is situated between the middle band (20-day SMA at $48.68) and the upper band ($53.58).
  • The price has moved from near the lower band ($43.78) just a few sessions ago, indicating a strong rebound.
  • The bandwidth (Upper - Lower = $9.80) is relatively wide, reflecting elevated recent volatility, particularly around the events of early May.
  • The current position suggests the stock is in a neutral-to-bullish zone, with room to move towards the upper band.

RSI

RSI(14)
51.78
RSI(6)
62.37
Overbought
70+
Oversold
30-
AI Analysis
  • The RSI_6 (6-day) is at 62.37, which is approaching the overbought threshold of 70, suggesting the short-term rally may be getting extended.
  • The standard 14-day RSI is at a more neutral 51.78, indicating the medium-term momentum is balanced.
  • The divergence between the two (short-term overbought vs. medium-term neutral) warns that the recent spike needs consolidation or could face a short-term pullback.

KDJ

K
52.08
D
37.11
J
82.00
Trend
-
AI Analysis
  • The KDJ values show a bullish configuration: K (52.08) > D (37.11), and the J value is extremely high at 82.00.
  • A J value above 80 is traditionally considered overbought.
  • This aligns with the RSI_6 reading, reinforcing the view that the stock has experienced a very sharp short-term upward move and may be due for a pause or minor retracement.

Chip distribution

How chip distribution helps you?
Chip distribution summary
  • An estimated 63.31% of chips are currently profitable with an average cost basis of $47.87, and the price is now above this average cost, which could reduce immediate selling pressure.
  • An estimated 63.31% of chips (estimated holdings) are currently in a profitable position, with an average cost basis of $47.87.
  • The current price ($49.06) is just above this average cost.
  • The 70% cost concentration range is between $46.18 and $53.10, and the 90% range is between $45.11 and $55.56.
  • The concentration values (70 concentration: 6.96%, 90 concentration: 10.38%) are relatively low, indicating that holdings are somewhat dispersed across this price range rather than tightly clustered.
  • This can mean there is no single, massive cost level that will act as an absolute support or resistance, but it also suggests the stock may lack a strong, unified base of long-term holders at a specific price.
  • The fact that the price is now above the average cost and within the broad 90% range suggests the majority of recent buyers are at or near breakeven, which could reduce immediate selling pressure from this cohort.
No chart data

Data is estimated based on turnover rate, high, low, open, and close prices. Profit ratios may vary significantly across different brokerage tools.